Sanjaya brings over 25 years of expertise in biotherapeutics and a track record of innovative work across multiple therapeutic areas. A leader in immunomodulation, Sanjaya has developed novel biologics in the fields of immunology, oncology, retinal, metabolic, and neurological diseases and is a co-inventor of several key molecules, including SKYRIZI®, EBGLYSS™, PRAXBIND®, ligelizumab, and lampalizumab.

In his previous role as head of Johnson & Johnson (J&J) biotherapeutics, Sanjaya led the global therapeutics discovery organization and set the strategic direction for expanding J&J's biotherapeutic portfolio and platforms. Prior to J&J, he served as vice president of biotherapeutics discovery at Boehringer Ingelheim, where he built and led a global team to establish a highly competitive pipeline. Sanjaya’s industry career began at Tanox Inc., where he was head of biotherapeutics until the company was acquired by Genentech.

Sanjaya co-founded Aliada Therapeutics, a neuroscience-blood-brain barrier platform company recently acquired by AbbVie, and serves as a Venture Partner at Omega Funds, a leading life sciences investment firm. He has also held an academic position at the Institute of Life Sciences in India. He has authored numerous peer-reviewed publications and with over 60 patents, his contributions span basic research, platform technologies, and biologic molecules.

Sanjaya earned his PhD in molecular biology from Banaras Hindu University and completed postdoctoral research at MD Anderson Cancer Center.